Analyst Ratings For Gilead Sciences (NASDAQ:GILD)
Today, Bank of America Corp reiterated its Neutral rating on Gilead Sciences (NASDAQ:GILD) with a price target of $68.19.
There are 10 hold ratings, 15 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Gilead Sciences (NASDAQ:GILD) is Buy (Score: 2.65) with a consensus target price of $83.74 per share, a potential 22.81% upside.
Some recent analyst ratings include
3/13/2017-Bank of America Corp Reiterated Rating of Neutral.
3/13/2017-Goldman Sachs Group Inc Reiterated Rating of Neutral.
3/11/2017-Barclays PLC Reiterated Rating of Outperform.
3/1/2017-Credit Suisse Group AG Reiterated Rating of Buy.
2/16/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
Dividend information for Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $1.88 with a yield of 2.76%.
Dividend History for Gilead Sciences (NASDAQ:GILD)
On 2/7/2017 Gilead Sciences announced a quarterly dividend of $0.52 3.11% with an ex dividend date of 3/14/2017 which will be payable on 3/30/2017.
On 11/1/2016 Gilead Sciences announced a quarterly dividend of $0.47 2.59% with an ex dividend date of 12/13/2016 which will be payable on 12/29/2016.
On 7/25/2016 Gilead Sciences announced a quarterly dividend of $0.47 2.32% with an ex dividend date of 9/14/2016 which will be payable on 9/29/2016.
On 4/28/2016 Gilead Sciences announced a quarterly dividend of $0.47 2.13% with an ex dividend date of 6/14/2016 which will be payable on 6/29/2016.
On 2/2/2016 Gilead Sciences announced a quarterly dividend of $0.43 1.99% with an ex dividend date of 3/14/2016 which will be payable on 3/30/2016.
On 10/27/2015 Gilead Sciences announced a quarterly dividend of $0.43 1.59% with an ex dividend date of 12/14/2015 which will be payable on 12/30/2015.
On 7/28/2015 Gilead Sciences announced a quarterly dividend of $0.43 1.49% with an ex dividend date of 9/14/2015 which will be payable on 9/29/2015.
Recent Insider Trading Activity For Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) has insider ownership of 1.40% and institutional ownership of 74.19%.
On 1/3/2017 John C Martin, Insider, sold 73,337 with an average share price of $73.59 per share and the total transaction amounting to $5,396,869.83. View SEC Filing
On 11/18/2016 John W Madigan, Director, sold 105,000 with an average share price of $74.86 per share and the total transaction amounting to $7,860,300.00. View SEC Filing
On 10/3/2016 John C Martin, Insider, sold 100,000 with an average share price of $77.63 per share and the total transaction amounting to $7,763,000.00. View SEC Filing
On 9/22/2016 Gregg H Alton, EVP, sold 5,000 with an average share price of $81.84 per share and the total transaction amounting to $409,200.00. View SEC Filing
On 9/6/2016 John F Milligan, Insider, sold 70,000 with an average share price of $77.74 per share and the total transaction amounting to $5,441,800.00. View SEC Filing
On 9/1/2016 John C Martin, Insider, sold 100,000 with an average share price of $77.48 per share and the total transaction amounting to $7,748,000.00. View SEC Filing
On 8/24/2016 Kevin E Lofton, Director, sold 3,500 with an average share price of $81.97 per share and the total transaction amounting to $286,895.00. View SEC Filing
About Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company’s liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company’s cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company’s Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.
Recent Trading Activity for Gilead Sciences (NASDAQ:GILD)
Shares of Gilead Sciences closed the previous trading session at 67.64 down -0.55 -0.81% with 14,480,510 shares trading hands.
The post Analyst Activity – Bank of America Corp Reiterates Neutral on Gilead Sciences (NASDAQ:GILD) appeared first on Market Exclusive.